# BGSF, Inc.: overview BGSF · NYSE · CIK 1474903 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 28 Pages: [Overview](/companies/bgsf.md) · [Financials](/companies/bgsf/financials.md) · [Filings](/companies/bgsf/filings.md) · [Insiders](/companies/bgsf/insiders.md) Latest reported revenue: [$22.3m](/filings/0001474903-26-000070.md) for Q2 FY2026, three months to 2026-06-28, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:Revenues, accession 0001474903-26-000070). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-29) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-28) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [29.8](/filings/0001474903-26-000030.md) | [24.3](/filings/0001474903-26-000030.md) | [20.9](/filings/0001474903-26-000056.md) | [23.5](/filings/0001474903-26-000070.md) | [26.9](/filings/0001474903-26-000030.md) | [22.0](/filings/0001474903-26-000030.md) | [20.9](/filings/0001474903-26-000056.md) | [22.3](/filings/0001474903-26-000070.md) | | Gross margin | % | [35.9%](/filings/0001474903-26-000030.md) | [35.9%](/filings/0001474903-26-000030.md) | [36.2%](/filings/0001474903-26-000056.md) | [35.8%](/filings/0001474903-26-000070.md) | [35.9%](/filings/0001474903-26-000030.md) | [35.0%](/filings/0001474903-26-000030.md) | [35.5%](/filings/0001474903-26-000056.md) | [35.5%](/filings/0001474903-26-000070.md) | | Operating margin | % | [(3.4%)](/filings/0001474903-25-000142.md) | [(8.8%) d](/filings/0001474903-26-000030.md) | [(8.5%)](/filings/0001474903-26-000056.md) | [(16.9%)](/filings/0001474903-26-000070.md) | [(3.5%)](/filings/0001474903-25-000142.md) | [(8.0%) d](/filings/0001474903-26-000030.md) | [(7.4%)](/filings/0001474903-26-000056.md) | [(5.3%)](/filings/0001474903-26-000070.md) | | Net margin | % | [(2.7%)](/filings/0001474903-26-000030.md) | [(4.0%)](/filings/0001474903-26-000030.md) | [(3.5%)](/filings/0001474903-26-000070.md) | [(15.9%)](/filings/0001474903-26-000070.md) | [(21.6%)](/filings/0001474903-26-000030.md) | [(5.3%)](/filings/0001474903-26-000030.md) | [(2.3%)](/filings/0001474903-26-000070.md) | [(3.7%)](/filings/0001474903-26-000070.md) | | Diluted EPS | $ per share | [(0.07)](/filings/0001474903-25-000142.md) | not reported | [(0.06)](/filings/0001474903-26-000030.md) | [(0.34)](/filings/0001474903-26-000030.md) | [(0.52)](/filings/0001474903-26-000030.md) | [(0.10)](/filings/0001474903-26-000030.md) | not reported | not reported | | Free cash flow | $m | [6.5 d](/filings/0001474903-25-000142.md) | [3.0 d](/filings/0001474903-26-000030.md) | [1.0](/filings/0001474903-26-000056.md) | [2.1 d](/filings/0001474903-26-000070.md) | [(4.9) d](/filings/0001474903-25-000142.md) | [1.7 d](/filings/0001474903-26-000030.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-26) | FY2022 (2023-01-01) | FY2023 (2023-12-31) | FY2024 (2024-12-29) | FY2025 (2025-12-28) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [239](/filings/0001474903-24-000026.md) | [298](/filings/0001474903-25-000016.md) | [125](/filings/0001474903-26-000030.md) | [104](/filings/0001474903-26-000030.md) | [93.3](/filings/0001474903-26-000030.md) | | Gross margin | % | [33.9%](/filings/0001474903-24-000026.md) | [34.7%](/filings/0001474903-25-000016.md) | [39.8%](/filings/0001474903-26-000030.md) | [36.8%](/filings/0001474903-26-000030.md) | [35.7%](/filings/0001474903-26-000030.md) | | Operating margin | % | [6.1%](/filings/0001474903-24-000026.md) | [5.5%](/filings/0001474903-25-000016.md) | [2.5%](/filings/0001474903-26-000030.md) | [(5.6%)](/filings/0001474903-26-000030.md) | [(9.5%)](/filings/0001474903-26-000030.md) | | Net margin | % | [5.9%](/filings/0001474903-24-000026.md) | [8.5%](/filings/0001474903-25-000016.md) | [(8.2%)](/filings/0001474903-26-000030.md) | [(3.2%)](/filings/0001474903-26-000030.md) | [(12.2%)](/filings/0001474903-26-000030.md) | | Diluted EPS | $ per share | [1.35](/filings/0001474903-24-000026.md) | [2.42](/filings/0001474903-25-000016.md) | [(0.95)](/filings/0001474903-26-000030.md) | [(0.31)](/filings/0001474903-26-000030.md) | [(1.04)](/filings/0001474903-26-000030.md) | | Free cash flow | $m | [3.5](/filings/0001474903-24-000026.md) | [(12.8)](/filings/0001474903-25-000016.md) | [18.2](/filings/0001474903-26-000030.md) | [23.2](/filings/0001474903-26-000030.md) | [0.0](/filings/0001474903-26-000030.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bgsf/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.8m | 484,995 | | Reduced −5,325 | | [Pacific Ridge Capital Partners, LLC](/funds/1591546.md) | 2026-06-30 | $2.2m | 381,083 | | Reduced −2,954 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $936.9k | 164,086 | | Added +8,835 | | [SEI INVESTMENTS CO](/funds/350894.md) | 2026-06-30 | $804.0k | 140,798 | | Reduced −140,798 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $792.5k | 138,783 | | Reduced −7,424 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $640.3k | 112,113 | | Added +2,104 | | [BRIDGEWAY CAPITAL MANAGEMENT, LLC](/funds/1107261.md) | 2026-06-30 | $580.3k | 101,635 | | Added +2,879 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $502.3k | 87,961 | | Added +36,680 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $462.6k | 81,014 | | Added +10,136 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $346.4k | 60,657 | | Added +452 | ## Recent filings [All 603 filings](/companies/bgsf/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-16 | 17:54 ET | [DEF 14A](/filings/0001474903-26-000084.md) | Proxy statement, period 2025-12-28 | 0001474903-26-000084 | | 2026-08-05 | 17:07 ET | [8-K](/filings/0001474903-26-000071.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001474903-26-000071 | | 2026-08-05 | 16:58 ET | [10-Q](/filings/0001474903-26-000070.md) | Quarterly report, period 2026-06-28 | 0001474903-26-000070 | | 2026-06-08 | 17:57 ET | [8-K](/filings/0001474903-26-000066.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001474903-26-000066 | | 2026-05-14 | 19:44 ET | [10-Q/A](/filings/0001474903-26-000056.md) | Quarterly report, amended, period 2026-03-29 | 0001474903-26-000056 | | 2026-05-06 | 16:13 ET | [8-K](/filings/0001474903-26-000041.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001474903-26-000041 | | 2026-05-06 | 16:11 ET | [10-Q](/filings/0001474903-26-000040.md) | Quarterly report, period 2026-03-29 | 0001474903-26-000040 | | 2026-03-30 | 17:43 ET | [10-K](/filings/0001474903-26-000030.md) | Annual report, period 2025-12-28 | 0001474903-26-000030 | | 2026-03-11 | 17:14 ET | [8-K](/filings/0001474903-26-000015.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001474903-26-000015 | | 2026-03-02 | 17:02 ET | [8-K](/filings/0001474903-26-000012.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001474903-26-000012 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 28, 2025](/filings/0001474903-26-000030.md), filed Mar 30, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-28, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/cb556189-4e84-494f-aad9-cc16567afa0c) ## About the filer - CIK: 1474903 - Tickers: BGSF - Exchange: NYSE - SIC code: 7363 Services-Help Supply Services - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 11:10 ET. No prices; not investment advice.